ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced that the Company and Massachusetts General Hospital (MGH) have entered into a definitive agreement to collaborate in the development of clinical diagnostic tests that will expand the use of personalized medicine for the identification and treatment of solid tumors. The fully executed agreement will build upon a solid tumor genotyping and pharmacogenomics testing platform that MGH has been offering to its patients for the past few years. This genotyping platform will allow for the simultaneous assessment of more than 100 cancer mutations in clinical tumor specimens, allowing for the optimal choice of targeted therapies in each patient. In addition, the agreement is expected to accelerate research, especially involving clinical correlations with drug responses that will be accessible to other entities, including pharmaceutical companies that are expected to cooperate in the development of personalized medicine therapies. This joint project is based on innovative technology that may prove superior to current diagnostic methodologies.
